2010 Press releases


Displaying 1 - 10 of 29



20 December 2010
Clavis Pharma’s elacytarabine granted FDA Fast Track designation in USA

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that its clinical development programme with elacytarabine for the treatment of patients with acute myeloid leukaemia (AML) ...


10 December 2010
Prospectus approved

9 December 2010
Clavis Pharma’s NOK 154 million Private Placement approved at Extraordinary General Meeting

Clavis Pharma ASA (OSE: CLAVIS) announces that all items proposed to shareholders at its extraordinary general meeting held today in Oslo were resolved according the Board's proposal...


1 December 2010
Clavis Pharma presented at the Nordic Health Care Conference 2010

19 November 2010
Registration to attend the Extraordinary General Meeting on 9 December 2010

18 November 2010
Clavis Pharma raises NOK 154 million (EUR 19 million) in a private placement

Clavis Pharma ASA (OSE: CLAVIS) (the "Company") today announces that the Company has raised NOK 154 million ..


18 November 2010
Notice of Extraordinary General Meeting

11 November 2010
Invitation Meeting & Conference Call for Clavis Pharma's new $205 million deal with Clovis Oncology for the development & commercialisation of anti-cancer agent CP-4126 in Asia and Rest of the World

11 November 2010
Clavis Pharma and Clovis Oncology Extend Partnership and Sign New $205 Million Deal for the Development and Commercialisation of Anti-Cancer Agent CP-4126 in Asia and Rest of the World

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug discovery and development company, and Clovis Oncology, Inc., announced today a new agreement ...


21 October 2010
Clavis Pharma - Third Quarter Report 2010